NRX Pharmaceuticals Inc Ordinary Shares NRXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
-
New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA
-
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma (NASDAQ:MDCX)
-
GLOBAL MARKETS SPOTLIGHT: New to The Street Show #748 Delivers High-Impact CEO Interviews and Spotlight TV Commercials Across Bloomberg to 250M+ Households Worldwide
-
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
Trading Information
- Previous Close Price
- $4.18
- Day Range
- $4.08–4.51
- 52-Week Range
- $1.62–5.06
- Bid/Ask
- $4.27 / $4.46
- Shares Outstanding
- 42.80M
- Market Cap
- $190.89M
- Volume/Avg
- 751,937 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 46.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://nrxpharma.com
Valuation
|
Metric
|
NRXP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 46.27 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NRXP
|
|---|---|
Quick Ratio | 0.27 |
Current Ratio | 0.29 |
Interest Coverage | −26.16 |
Quick Ratio
NRXP
Profitability
|
Metric
|
NRXP
|
|---|---|
Return on Assets (Normalized) | −182.89% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NRXP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?pF^sL | LOCK|svhV& | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|LMLyK^S | LOCK|>??? | $70B | |||
| argenx SE ADR
ARGX
| LOCK|nr$@><# | LOCK|?> | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#Sh<>&h | LOCK|r^k | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<&>%Gt | LOCK|t<#N | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$s^<?hR | LOCK|>jj@z | $25B | |||
| Moderna Inc
MRNA
| LOCK|@C^%Tf | LOCK|yv | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|h$S>^%F | LOCK|@#m | $23B | |||
| Incyte Corp
INCY
| LOCK|QYLB^&# | LOCK|mF | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|y$x^Y^Q | LOCK|%h | $16B |
United States